- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03757377
Moderato System in Patients With Hypertension
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a dual chamber pacemaker in order to reduce their blood pressure.
In this amended CS-03 protocol Version 3.0, the study will evaluate the safety and efficacy in a randomized, double-blind study following active treatment vs. a control patient population for a period of 3 month for efficacy and 12 months for safety (In comparison to 6 months for patients under protocol CS-03 Ver 1.1, NCT02837445).
The device will be considered to have a clinical effectiveness with regard to its anti-hypertension function if there is a statistically significant and clinically meaningful reduction in mean 24-hour ambulatory systolic blood pressure in the treatment group compared to the control group. The primary efficacy endpoint will be evaluated 3 months after randomization. The Primary safety analysis will compare the treatment and the control after 12 months of treatment.
Study Overview
Status
Intervention / Treatment
Detailed Description
Protocol CS-03 Ver 1.1 (NCT02837445) was amended at the advice of the Scientific Advisory to protocol CS-03 Version 3.0 with more stringent hypertension inclusion criteria and different observation intervals for efficacy and safety.
In CS-03 Version 3.0 the time of the primary efficacy endpoint was reduced from 6 months to 3 months post randomization which was deemed a suitable interval for the chronic effect, whereas for the safety endpoint, the period was lengthened to 12 months post randomization to better monitor potential risks of the treatment on cardiac function (Blinding period was increased from 6 months to 12 months). Protocols were thus split in order to allow better clarification to the difference in the time to the primary endpoints for efficacy and safety between the two CIP versions and simplify data analysis.
Protocol Ver 3.0 prescribes data analysis of all patients randomized under version 1.1 to be performed once they complete the 6 months follow-up as set in protocol version 1.1 (NCT0283744). It is expected that ~40 patients will be randomized according to protocol version 1.1 prior to the enrollment of patients according to protocol version 3.0. The results will be considered as interim analysis.
The recruitment for the protocol version 1.1 is now completed. Total of 47 patients were randomized according to protocol version 1.1 and all patients completed the follow-up period for the primary endpoint.
Patients are currently being followed up for the study "extension period".
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1090
- UZ Brussel - Heart Rhythm Management Center
-
-
-
-
-
Vilnius, Lithuania, 08661
- Vilnius University Hospital Santariskiu Klinikos
-
-
-
-
-
Warsaw, Poland, 02-097
- Samodzielnym Publicznym Centralnym Szpitalem Klinicznym
-
Zabrze, Poland, 41-800
- Silesian Center for Heart Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Requirement of dual chamber pacemaker or upgrade from a single chamber to a dual chamber pacemaker.
- Stable (at least 6 weeks) hypertension treatment with at least 1 anti-hypertensive drug, which is anticipated to be maintained without changes. Stable is defined as being in the same drug regimen, and the dose of each drug(s) no more than 50% reduced or 100% increased over the past 6 weeks.
- Average 24-hour ambulatory systolic blood pressure ≥ 130 mmHg (with directly observed medical therapy, DOT) and office blood pressure ≥140 mmHg.
- Subject is able to comply with study visits for at least 13 months (e.g., is capable and willing to travel to/from the center for all scheduled study visits).
Exclusion Criteria:
- Known secondary cause of HTN.
- Average ambulatory or office systolic BP > 195 mmHg.
- Permanent atrial fibrillation.
- History of significant paroxysmal atrial fibrillation/flutter burden (defined as >25% of beats).
- Cardiac ejection fraction <50%.
- Symptoms of heart failure, NYHA Class II or greater.
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal thickness ≥ 15 mm.
- Subject is on dialysis.
- Subject has an estimated Glomerular Filtration Rate < 30 ml/min/1.73 m²
- Prior neurological events (stroke or TIA) within the past year or events at a prior time that has resulted in residual neurologic deficit.
- Carotid artery disease.
- Known autonomic dysfunction.
- History of clinically significant untreated ventricular tachyarrhythmia or has experienced cardiac arrest.
- Previous active device-based treatment for HTN.
- Existing implant, other than a pacemaker that needs replacing.
- Subject is or has the possibility of becoming pregnant and is unwilling of contraception during the study.
- Subject is unwilling or cannot provide Informed Consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BackBeat Moderato System (PHC ON)
Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
|
Eligible patients randomized after optimization phase to PHC ON for 12 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
|
Placebo Comparator: BackBeat Moderato System (PHC OFF)
Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
|
Eligible patients randomized after optimization phase to PHC OFF for 12 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of composite of major cardiac events
Time Frame: 12 months post Randomization
|
including heart failure, clinically significant arrhythmias eg, persistent or increased atrial fibrillation, serious ventricular arrhythmias, myocardial infarction, stroke, heart failure, renal failure and/or related safety events that result in death
|
12 months post Randomization
|
Change in average 24 hour systolic ambulatory blood pressure
Time Frame: Week 3 pre Randomization and 3 months post Randomization
|
Week 3 pre Randomization and 3 months post Randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karl-Heinz Kuck, Prof. MD, Asklepios Klinik St. Georg
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS-03 Ver 3.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrioventricular Block
-
University Hospital of FerraraRecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Left Bundle-Branch Block | Bundle-Branch Block | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Atrioventricular Block | Heart Failure, Systolic | Ventricular Arrythmia | Heart Failure,Congestive | Bradyarrhythmia | Heart Arrhythmia | Reduced... and other conditionsItaly
-
University of Sao PauloUnknownCongenital Complete Atrioventricular Heart Block | High Grade Atrioventricular Block | Postoperative Complete Heart BlockBrazil
-
Tongji HospitalGuangdong Provincial People's Hospital; Wuhan Asia Heart Hospital; Fu Wai Hospital... and other collaboratorsUnknownBradycardia | Sick Sinus Syndrome | High Degree Second Degree Atrioventricular Block | Complete Atrioventricular BlockChina
-
Tongji HospitalGuangdong Provincial People's Hospital; Wuhan Asia Heart Hospital; Fu Wai Hospital... and other collaboratorsUnknownBradycardia | Sick Sinus Syndrome | Complete Atrioventricular Block | High Degree Second Degree Atrioventricular Block (Disorder)China
-
Gianluca BottoUnknownFirst Degree Atrioventricular BlockItaly
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrioventricular Conduction BlockUnited States, Belgium, Hong Kong, Malaysia, Spain, Austria, Denmark, France
-
West China HospitalRecruitingAVB - Atrioventricular BlockChina
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrioventricular Conduction BlockDenmark, United States, Belgium, Italy, Malaysia, Spain, France, Austria, Czechia
-
Quovadis AssociazioneRecruitingSinus Node Disease | Atrioventricular; Block, Second Degree (Types I and II)Italy
-
NYU Langone HealthRecruitingAVB - Atrioventricular Block | Fetal AVBUnited States, Canada
Clinical Trials on BackBeat Moderato System
-
BackBeat Medical IncRecruitingHypertension,Essential | Systolic HypertensionPoland, Czechia, Hungary
-
BackBeat Medical IncMassachusetts General Hospital; MLM Medical Labs GmbH; nabios GmbHCompletedBradycardia | Atrioventricular Block | Hypertension Resistant to Conventional TherapyHungary, Austria, Chile, Latvia, Czechia, Lithuania, Netherlands
-
BackBeat Medical IncCD LeycomNot yet recruiting
-
BackBeat Medical IncActive, not recruiting
-
BackBeat Medical IncCompleted
-
BackBeat Medical IncCD LeycomRecruitingBradycardia | Hypertension, SystolicCzechia
-
Orchestra BioMed, IncMedtronicRecruitingHypertension | Hypertension, Systolic | Hypertension,EssentialUnited States, Czechia, Hungary
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil